Sleep disturbance in Inflammatory Bowel Disease: prevalence and risk factors – A cross-sectional study von Marinelli, C., Savarino, E. V., Marsilio, I., Lorenzon, G., Gavaruzzi, T., D’Incà, R., Zingone, F.

Volltext

Inflammatory bowel diseases and spondyloarthritis: a focus on female patients von Caranfil, C, Lorenzon, G, Barberio, B, Ramonda, R, Savarino, E V, Zingone, F

Volltext

Frontoparietal atrophy trajectories in cognitively unimpaired elderly individuals using longitudinal Bayesian clustering von Lorenzon, G., Poulakis, K., Mohanty, R., Kivipelto, M., Eriksdotter, M., Ferreira, D., Westman, E.

Volltext

Letter: oesophageal histological abnormalities and GERD ‐ an underestimated relationship requiring more attention von Savarino, E., Lorenzon, G., Facchin, S., Savarino, V.

Volltext

Differential response to donepezil in MRI subtypes of mild cognitive impairment von Diaz-Galvan, Patricia, Lorenzon, Giulia, Mohanty, Rosaleena, Mårtensson, Gustav, Cavedo, Enrica, Lista, Simone, Vergallo, Andrea, Kantarci, Kejal, Hampel, Harald, Dubois, Bruno, Grothe, Michel J, Ferreira, Daniel, Westman, Eric

Volltext

P.14.12 ADHERENCE TO OUTPATIENT FOLLOW-UP VISIT IN IBD PATIENTS von Vettorato, M.G, Bartolo, O, Girardin, G, Rigo, A, Bellia, S, Lorenzon, G, Simonetti, F, Padovese, F, Savarino, E.V, Sturniolo, G.C, D'Incà, R

Volltext

GLPG0187 inhibits progression of established bone metastasis and achieves maximum efficacy when combined with standard-of-care metastatic breast cancer treatments von Clément-Lacroix, P, Berrocal, E, Heckmann, B, Wigerinck, P, Lorenzon, G, Pujuguet, P

Volltext

Evidence of extended [CII] and dust emission in local dwarf galaxies von Romano, M., Donevski, D., Junais, Nanni, A., Ginolfi, M., Jones, G. C., Shivaei, I., Lorenzon, G., Hamed, M., Salak, D., Sawant, P.

Volltext

PP 87 Molecular imaging demonstrates GLPG0187, a small-molecule integrin antagonist, binds to RGD-integrin receptors in vivo and is efficacious in tumor and metastasis models von Pujuguet, P, Berrocal, E, Heckmann, B, Wigerinck, P, Lorenzon, G, Clément-Lacroix, P, Bormans, G, Deroose, C

Volltext

A microtiter plate assay for total glutathione and glutathione disulfide contents in cultured/isolated cells: performance study of a new miniaturized protocol von VANDEPUTTE, C, GUIZON, I, GENESTIE-DENIS, I, VANNIER, B, LORENZON, G

Volltext

OC.05.1 IDENTIFICATION OF MARKERS OF OXIDATIVE STRESS IN CELIAC DISEASE von Marsilio, I., Cardin, R., Maniero, D., Lorenzon, G., Scaramuzza, G., Savarino, E.V., Farinati, F., Zingone, F.

Volltext

T02.02.7 A NUTRITIONAL KNOWLEDGE SURVEY IN PATIENTS WITH COELIAC DISEASE von Marsilio, I., Maniero, D., Marinelli, C., Barberio, B., Lorenzon, G., D'Odorico, A., Savarino, E.V., Zingone, F.

Volltext

N47 Spiritual needs of patients with IBD: preliminary results of a pilot study von Starnella, G, Rosato, I, Canova, C, Savarino, E V, Zingone, F, Barberio, B, Lorenzon, G, Gregori, D, Comoretto, R I, Martinato, M

Volltext

OC.06.6 COMPARATIVE ASSESSMENT C-REACTIVE PROTEIN BETWEEN A POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (IMMUNONEPHELOMETRIC TESTING) von Lorenzon, G., Marsilio, I., Maniero, D., Rigo, A., Barberio, B., Zingone, F., Bahur, B., Bray, K., Savarino, E.V.

Volltext

Correction: Differential response to donepezil in MRI subtypes of mild cognitive impairment von Diaz-Galvan, Patricia, Lorenzon, Giulia, Mohanty, Rosaleena, Mårtensson, Gustav, Cavedo, Enrica, Lista, Simone, Vergallo, Andrea, Kantarci, Kejal, Hampel, Harald, Dubois, Bruno, Grothe, Michel J, Ferreira, Daniel, Westman, Eric

Volltext

T02.02.2 INFLAMMATORY BOWEL DISEASES AND CELIAC DISEASE PATIENTS' NUTRITIONAL KNOWLEDGE von Marsilio, I., Inferrera, M., Maniero, D., Marinelli, C., Lorenzon, G., D'Incà, R., D'Odorico, A., Savarino, E.V., Zingone, F.

Volltext

T04.02.9 THE EFFECTIVENESS OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE IN DIFFERENT REAL-WORD SCENARIOS von Zingone, F., Barberio, B., Compostella, F., D'Inca', R., Marinelli, C., Inferrera, M., Marsilio, I., Lorenzon, G., Savarino, E.V.

Volltext

T04.02.8 INFLIXIMAB ORIGINATOR, INFLIXIMAB BIOSIMILAR AND ADALIMUMAB ARE EQUALLY EFFECTIVE AND SAFE IN ULCERATIVE COLITIS AND CROHN'S DISEASE – A REAL-LIFE COHORT STUDY von Barberio, B., Zingone, F., D'Incà, R., Rovigo, L., Marinelli, C., Massimi, D., Gubbiotti, A., Ghisa, M., Lorenzon, G., Savarino, E.

Volltext

AF.48 COMPARATIVE ASSESSMENT OF ADALIMUMAB TROUGH LEVELS BETWEEN POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (ENZYME LINKED IMMUNOSORBENT ASSAY) IN PATIENTS WITH INFLAMMATOR... von Marsilio, I., Maniero, D., Lorenzon, G., Rigo, A., Cardin, R., Facchin, S., Barberio, B., D’Incà, R., Zingone, F., Bahur, B., Bray, K., Savarino, E.

Volltext

AF.56 COMPARATIVE ASSESSMENT OF INFLIXIMAB TROUGH LEVELS BETWEEN POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (ENZYME LINKED IMMUNOSORBENT ASSAY) IN PATIENTS WITH INFLAMMATOR... von Maniero, D., Lorenzon, G., Marsilio, I., Rigo, A., Cardin, R., Facchin, S., Barberio, B., D’Incà, R., Zingone, F., Bahur, B., Bray, K., Savarino, E.V.

Volltext